Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

SII partners with DNDi to develop affordable dengue treatment, aiming to save lives in LMICs and endemic countries.

Watch quick-thinking elephant rescue drowning gazelle with its trunk Rick Carlisle Provides Surprising Myles Turner Update ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

The Serum Institute of India (SII), the world’s largest vaccine manufacturer and Drugs for Neglected Diseases initiative ...

Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell ...

Key Takeaways AI accelerates drug approvals in 2025 by streamlining clinical data analysis.Advanced AI tools reduce costs and time for new medicine development.

NEW DELHI, (IANS) – India is emerging as a favorable destination to conduct clinical trials, according to a report released by PwC India and the US-India Chamber of Commerce (USAIC) on May 3.

As India enters peak season for fungal infections, a breakthrough in natural medicine is making headlines: Skin Revive, a ...

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five ...

Lucknow: A recent study conducted at King George's Medical University (KGMU) found that piroxicam, a commonly used pain ...

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).